Fasenra pen 30 MG/mlml
Ended Awarded Last action
- Contract number
- SPE2DR26FHNW1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $24,938
Award facts
- Contract value 100% obligated
- $24,937.50 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $24,937.50 to DMS Pharmaceutical Group Inc. for FASENRA (benralizumab) 30 mg/mL on January 30, 2026, with an ultimate completion date of February 2, 2026. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. The delivery order falls under DMS Pharmaceutical Group's broader Indefinite Delivery Contract (IDC) with the DLA, specifically the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which carries a $499.9 billion ceiling and extends through December 31, 2036.
The PPV-G GEN V represents a comprehensive $30.3 billion federal acquisition strategy designed to streamline pharmaceutical supply to Department of Defense military healthcare facilities worldwide. As one of multiple regional prime vendor contractors under this framework, DMS Pharmaceutical Group supplies a diverse portfolio including branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals to support DoD medical operations. This particular delivery order for FASENRA, a biologic immunosuppressant used in respiratory and other therapeutic applications, exemplifies the company's role in providing specialized pharmaceutical products critical to military medical readiness. The contract structure enables DLA to issue firm fixed-price delivery orders as recurring medical supply needs arise across the global military healthcare system.
Quick answers
Who was awarded contract SPE2DR26FHNW1?
SPE2DR26FHNW1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 30, 2026.
How much is contract SPE2DR26FHNW1 worth?
The government has obligated $24,938 on SPE2DR26FHNW1.
Is contract SPE2DR26FHNW1 an order under another contract?
Yes. SPE2DR26FHNW1 is a delivery order under SPE2DR25D9231, an indefinite delivery contract.
Was contract SPE2DR26FHNW1 competed?
The extent of competition for SPE2DR26FHNW1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award